Inflammatory markers in antipsychotic-naive patients with nonaffective psychosis and deficit vs. nondeficit features

被引:64
作者
Garcia-Rizo, Clemente [1 ]
Fernandez-Egea, Emilio [2 ,3 ]
Oliveira, Cristina [1 ]
Justicia, Azucena [2 ]
Bernardo, Miguel [1 ,4 ,7 ]
Kirkpatrick, Brian [5 ,6 ]
机构
[1] Univ Barcelona, Hosp Clin, Inst Neurosci, Schizophrenia Program,Dept Psychiat, E-08036 Barcelona, Spain
[2] Univ Cambridge, Addenbrookes Hosp, Dept Psychiat, Cambridge CB2 0QQ, England
[3] Cambridgeshire & Peterborough NHS Fdn Trust, Huntingdon PE29 3RJ, England
[4] Inst Biomed Res Agusti Pi i Sunyer IDIBAPS, Barcelona, Spain
[5] Texas A&M Univ, Coll Med, Dept Psychiat, Temple, TX 76508 USA
[6] Scott & White Healthcare, Temple, TX USA
[7] CIBERSAM, Madrid, Spain
关键词
Deficit schizophrenia; Interleukin; 6; C-reactive protein; Glucose tolerance; Negative symptoms; First episode psychosis; C-REACTIVE PROTEIN; PLACEBO-CONTROLLED TRIAL; IV FIELD TRIAL; SUMMER BIRTH; CELECOXIB AUGMENTATION; SERUM INTERLEUKIN-6; ADJUNCTIVE THERAPY; COX-2; INHIBITORS; DOUBLE-BLIND; SCHIZOPHRENIA;
D O I
10.1016/j.psychres.2011.08.014
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Newly diagnosed, antipsychotic-naive patients with nonaffective psychosis appear to have increases in pro-inflammatory cytokines. Patients characterized by primary, enduring negative symptoms (deficit symptoms) differ from patients without such features with regard to course of illness, treatment response, risk factors and metabolic disturbances. We hypothesized that they would also differ on concentrations of the inflammatory markers interleukin-6 (IL6) and C-reactive protein (CRP). Newly diagnosed, antipsychotic-naive patients with nonaffective psychosis were categorized into deficit (N = 20) and nondeficit (N = 42) groups, and were matched on age, gender, body mass index, smoking, cortisol level, socioeconomic status, and the severity of psychotic symptoms. Fasting concentrations of IL6 were significantly higher in deficit (mean [S.D.]) (8.0 pg/ml [12.7]) than nondeficit patients (0.3 pg/ml [1.3]). CRP levels were also significantly higher in the deficit patients (0.3 mg/dl [0.4]) vs. (0.2 mg/dl [0.4]), respectively. In contrast, 2-h glucose concentrations (2HG) in a glucose tolerance test were lower in the deficit than the nondeficit group. Our results show a double dissociation with regard to glucose intolerance and inflammation: the deficit group has greater inflammation, but less severe glucose intolerance. These results provide further evidence for the validity of the deficit/nondeficit categorization. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:212 / 215
页数:4
相关论文
共 51 条
[1]   The course of cognitive functioning in first episode psychosis: Changes over time and impact on outcome [J].
Addington, J ;
Saeedi, H ;
Addington, D .
SCHIZOPHRENIA RESEARCH, 2005, 78 (01) :35-43
[2]   Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients [J].
Akanji, Abayomi O. ;
Ohaeri, Jude U. ;
Al-Shammri, Suhail ;
Fatania, Hasmukh R. .
PSYCHIATRY RESEARCH, 2009, 169 (01) :56-61
[3]   Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial [J].
Akhondzadeh, Shahin ;
Tabatabaee, Maryam ;
Amini, Homayoun ;
Abhari, Seyed Ali Ahmadi ;
Abbasi, Seyed Hesamedin ;
Behnam, Behnaz .
SCHIZOPHRENIA RESEARCH, 2007, 90 (1-3) :179-185
[4]   Serum levels of soluble IL-2 receptor α, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration [J].
Akiyama, K .
SCHIZOPHRENIA RESEARCH, 1999, 37 (01) :97-106
[5]   Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: Findings from the CLAMORS study [J].
Arango, Celso ;
Bobes, Julio ;
Kirkpatrick, Brian ;
Garcia-Garcia, Margarida ;
Rejas, Javier .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 (12) :867-875
[6]   The effects of celecoxib augmentation on cytokine levels in schizophrenia [J].
Bresee, Catherine J. ;
Delrahim, Katia ;
Maddux, Rachel E. ;
Dolnak, Douglas ;
Ahmadpour, Oliver ;
Rapaport, Mark Hyman .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 (03) :343-348
[7]   Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives [J].
Carrizo, Edgardo ;
Fernandez, Virginia ;
Quintero, Jesius ;
Connell, Lissette ;
Rodriguez, Zulay ;
Mosquera, Monica ;
Acosta, Arnaldo ;
Baptista, Trino .
SCHIZOPHRENIA RESEARCH, 2008, 103 (1-3) :83-93
[8]   Three dimensions of clinical symptoms in elderly patients with schizophrenia: Prediction of six-year cognitive and functional status [J].
Chemerinski, Eran ;
Reichenberg, Abraham ;
Kirkpatrick, Brian ;
Bowie, Christopher R. ;
Harvey, Philip D. .
SCHIZOPHRENIA RESEARCH, 2006, 85 (1-3) :12-19
[9]   The stress cascade and schizophrenia: Etiology and onset [J].
Corcoran, C ;
Walker, E ;
Huot, R ;
Mittal, V ;
Tessner, K ;
Kestler, L ;
Malaspina, D .
SCHIZOPHRENIA BULLETIN, 2003, 29 (04) :671-692
[10]   Cytokines and CNS Development [J].
Deverman, Benjamin E. ;
Patterson, Paul H. .
NEURON, 2009, 64 (01) :61-78